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An Old Problem with a New Therapy: Gastrointestinal
Bleeding in Ventricular Assist Device Patients and Deep
Overtube-Assisted Enteroscopy
Konrad Sarosiek,* Linda Bogar,* Mitchell I. Conn,† Brendan O’Hare,† Hitoshi Hirose,* and
Nicholas C. Cavarocchi*

V

Conventional algorithms for diagnosis and treatment of gastrointestinal bleeding (GIB) in patients with nonpulsatile ventricular assist devices (VADs) may take days to perform while
patients require transfusions. We developed a new algorithm
based on deep overtube-assisted enteroscopy (DOAE) to facilitate a rapid diagnosis and treatment. From 2004 to 2012, 84
patients who underwent VAD placement in our institution,
were evaluated for episodes of GIB. Our new algorithm for
the management of GIB using DOAE was evaluated by dividing
the episodes into three groups: group A (traditional management without enteroscopy), group B (traditional management
with enteroscopy performed >24 hours after presentation), and
group C (new management algorithm with enteroscopy performed <24 hours after presentation). Gastrointestinal bleeding was observed in 14 (17%) of our study patients for a total of
45 individual episodes of which 28 met our criteria for subanalysis. Forty-one (84%) lesions were confined to the upper gastrointestinal tract with more than 91% of these lesions being
arteriovenous malformations. Average number of transfusions
in groups A, B, and C were 4.1, 6.3, and 1.3, respectively
(p = 0.001). The number of days to treatment was significantly
shorter in group C than group B (0.4 vs. 5.3 days, p = 0.0002).
Our new algorithm for the management of GIB using DOAE
targets the most common locations of bleeding found in this
patient population. When performed early, DOAE has the
potential to decrease the need for transfusions and allow for an
early diagnosis of GIB in VAD recipients. ASAIO Journal 2013;
59:384–389.

entricular assist devices (VADs) are used to treat advanced
heart failure either as a bridge to transplant or as destination
therapy.1 The majority of VADs currently implanted are continuous flow VADs (CFVADs) which create nonpulsatile blood
flow. These CFVADs are smaller and have increased longevity than the previous pulsatile VAD.2 Gastrointestinal bleeding
(GIB) has a reported incidence of 18%–40% in patients with
a VAD and is known to be much more common in patients
with the CFVAD.2,3 Treatment of each episode of GIB requires
the discontinuation of anticoagulation, which carries a risk for
developing a thrombus in the pump and possible subsequent
embolization.4 While a diagnosis is pursued, patients receive
blood transfusions which have been known to increase the risk
of infection and development of additional antibodies.5,6 The
traditional GIB algorithms for diagnosis and treatment can vary
widely from center to center and can take days to complete.
The current management of GIB in these VAD patients follows
the same algorithms used for the general population and does
not take into consideration the specialized needs of patients
who are on mechanical circulatory support. Patients with a
VAD who develop GIB need a faster diagnosis and treatment
so that anticoagulation can be resumed and transfusions can
be minimized. Thus, we reviewed our VAD patients who developed postoperative GIB to identify bleeding characteristics and
the management performed. We propose a new algorithm that
acts to shorten the time to diagnosis and treatment.
Methods
Patients

Key Words: gastrointestinal bleeding, ventricular assist
device, mechanical circulatory support, enteroscopy

After obtaining approval from the hospital internal review
board, a retrospective chart review was performed on all
patients receiving a VAD at our institution from 2004 to
2012. Demographic data were generated from The Society
of Thoracic Surgeons (STS) national database. Each chart was
reviewed looking for episodes of GIB from the date of VAD
implant through the duration of follow-up. A total of 84 patients
were identified of which 25 had a pulsatile VAD and 59 had a
CFVAD. Patient demographics were described in Table 1.
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Left Ventricular Assist Device Placement and Management
Two types of VADs were implanted; pulsatile VAD (Novacor and Abiomed AB5000) and CFVAD (HeartMate II and
Jarvik) during the study period. The Novacor (Novacor Corp.,
Oakland, CA), HeartMate II (Thoratec, Pleasanton, CA), and
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Table 1.  Demographics

Variable

Without Gastrointestinal
Bleeding
n = 70

With Gastrointestinal
Bleeding
n = 14

p Value

53 ± 13
51 (73%)

58 ± 10
11 (79%)

0.164
0.368

25 (36%)
45 (64%)

0 (0%)
14 (100%)

0.0079
0.0076

44 (63%)
16 (23%)
10 (14%)

7 (50%)
7 (50%)
0 (0%)

0.037
0.131
0.702

12 (17%)
27 (39%)
40 (57%)
52 (74%)
26 (37%)

3 (21%)
6 (43%)
9 (64%)
9 (64%)
3 (21%)

0.702
0.764
0.621
0.444
0.259

n = 45

n = 14

45 (100%)
45 (100%)

14 (100%)
14 (100%)

Age, mean ± SD
Male
Device
Pulsatile device
Nonpulsatile device
Race
Caucasian
African American
Other
Preoperative risk factors
Smoker
Diabetes
Hyperlipidemia
Hypertension
Cardiogenic shock
Postoperative discharge medications for
(for CFVAD only)
Anticoagulation
Antiplatelet

1.000
1.000

CFVAD, continuous flow ventricular assist device.

Abiomed AB5000 (Abiomed, Danvers, MA) were placed via
standard sternotomy between the left ventricular apex and
the ascending aorta, and the Jarvik 2000 (Jarvik Heart Inc.,
New York, NY) was placed via left thoracotomy between the
left ventricular apex and the mid-descending aorta. The VAD
pocket was created anterior to the diaphragm, and no VAD was
placed in the abdominal cavity. Device selection was individualized to each patient and the indications were as a bridge to
transplant for 54 (64%) patients and as destination therapy for
30 (36%). Postoperatively, all patients, regardless if on pulsatile
(Novacor and Abiomed) or CFVAD (HeartMate II and Jarvik),
were started on an antiplatelet drug on postoperative day 1
begun on a heparin bridge to Coumadin with a goal international normalized ratio (INR) of 1.8–2.0 on postoperative day
2. If patients had a history of atrial fibrillation, the target INR
was increased to 2.5. No patients in this study had a history of
documented GIB before VAD placement. All patients received
a proton-pump inhibitor after VAD insertion that was continued unless a contraindication existed.
Definition of Gastrointestinal Bleeding
An episode of GIB was defined as heme-positive stool or
hematemesis and a decrease in hemoglobin >1 g/dl. The resolution of GIB was defined as the stabilization of hemoglobin
for a minimum of 24 hours. Transfusion triggers were continued bleeding, hemoglobin level below 7 g/dl, or hemodynamic
instability. Gastrointestinal bleeding data acquisition was completed by January 2012.
Definition of Upper and Lower Gastrointestinal Tract
For the purpose of diagnosing GIB, traditionally the gastrointestinal tract is divided into upper (esophagus, stomach,
and duodenum) and lower (jejunum, ileum, colon, and rectum) regions. With the development of new technology which
allows the passage of an enteroscope from the mouth through

the duodenum into the distal small bowel, the upper gastrointestinal tract was redefined as esophagus, stomach, duodenum, jejunum, and ileum; or all areas accessible by the
enteroscope.7 The lower gastrointestinal tract was defined as
distal ileum, colon, rectum, and anus.
Traditional Gastrointestinal Bleeding Work-up
Patients presenting with GIB had all anticoagulation
stopped and gastroenterology was consulted for the appropriate workup. A traditional diagnostic algorithm is displayed in
Figure 1. Variations of this algorithm exist and the performed
tests dictated by the gastroenterology service.
New Technology and Algorithm
Deep overtube-assisted enteroscopy (DOAE) is a new and
emerging technology that uses a standard enteroscope with an
overtube to view the esophagus and stomach first, then the
bowel of the duodenum, jejunum, and ileum. There are three
different instruments used to perform this intervention: singleballoon (Olympus Optical, Tokyo, Japan), double-balloon
(Fujinon Inc., Saitama, Japan), and spirus enteroscopy (Spirus
Medical Inc., Stoughton, MA). The new technologies allow the
gastroenterologist to pleat the small bowel over the enteroscope
and overtube allowing them to visualize the small bowel distal
to the ligament of Treitz. Although three different instruments
exist to perform DOAE, preference for which instruments are
used lies with the individual gastroenterologist. Using this new
technology of enteroscopy, a new algorithm was created for
diagnosis and treatment of GIB (Figure 2).
Subgroup Analysis
In the 14 patients who experienced GIB, 45 individual
episodes were identified. To evaluate the efficacy of early use
of the DOAE in the work-up of GIB in VAD patients, a subgroup
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Figure 1. Traditional gastrointestinal bleeding management algorithm. DRE, digital rectal examination; EGD, esophagogastroduodenoscopy; GIB, gastrointestinal bleeding; NG, nasogastric lavage; RBC, red blood cell scan.

analyses was performed. Ten episodes of obvious colonic
bleeding, which were not eligible for DOAE, were treated
with colonoscopy and were not included in this subgroup
analysis. Five episodes of gastric bleeding were not included
because a standard DOAE includes an upper endoscopy;
thus these lesions would have been found and treated with
DOAE on initial pass. Two episodes were excluded because
of hemodynamic instability that prohibited the patient from
undergoing endoscopy. A total of 28 episodes in 12 patients
were eligible for our subgroup analysis, which were divided
into three groups based on the GIB work-up performed. Group
A (traditional management without DOAE) consisted of patients
with GIB who did not undergo DOAE at any point during
their hospital stay despite multiple other imaging modalities
(bleeding scans, upper endoscopy, colonoscopy, etc.) being
performed. The bleeding episode, in this subgroup, resolved
without a clear source being identified. Group B (traditional

management with DOAE performed >24 hours) consisted
of patients who underwent multiple imaging modalities
that ultimately resulted in enteroscopy being performed 24
hours or more after presentation to the hospital. Group C
(new management algorithm with enteroscopy <24 hours)
consists of individuals who received a DOAE within 24 hours
of presentation to the hospital as the initial test performed.
Outcome measures were the number of packed red blood cells
transfused, the number of days from presentation to treatment,
and the number of diagnostic/treatment procedures performed.
Statistics
Data were expressed as a mean with standard deviation
or number and corresponding percentage as appropriate.
Continuous variables were compared using a two-tailed Student’s t-test, and categorical variables were compared using

Figure 2. New algorithm for diagnosis and treatment of gastrointestinal bleeding in patients with a ventricular assist device. DOAE, deep
overtube-assisted enteroscopy; GIB, gastrointestinal bleeding; RBC, red blood cell scan.
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chi-square test or Fisher’s exact test. Comparisons of the aforementioned subgroups were performed using one-way ANOVA.
p < 0.05 was considered significant.

Table 2.  Location and Description of the Lesions Identified in
the 45 Episodes (49 Lesions)*
Location

Results
Among the 84 patients who received a VAD during the study
period, 14 (17%) developed at least one episode of GIB during mean follow-up period of 33.6 ± 19.8 months. Of these
patients with GIB, all 14 (100%) had a CFVAD; none were
pulsatile. Five (35%) patients developed the sentinel bleed
within 30 days from date of VAD implant, whereas eight (57%)
developed the first episode of GIB from 31 days to 1 year. There
was one outlier at 612 days who had one isolated incident.
The average time from implant to the first episode of GIB was
65 ± 62 days excluding the outlier mentioned earlier. Of the 14
patients, 10 patients (72%) developed a second bleed, seven
(50%) developed a third bleed, five (36%) a fourth, and three
(21%) a fifth. All 13 patients who developed a sentinel bleed
within 1 year of VAD implant had each subsequent bleeding
episode within 1 year of the initial event.
During the study period, a total 45 individual episodes of
GIB occurred in 14 patients. The mean INR on presentation of
a VAD patient with an episode of GIB was 1.85 ± 1.32, whereas
64% of the episodes had an INR <1.5. A variety of tests were
used to identify the location of the GIB. In the 45 episodes that
met the criteria for the definition of GIB, 49 individual sites
were identified for analysis with four episodes having multiple
locations of bleeding. Among the 49 lesions of GIB, 45 (92%)
were from arteriovenous malformations (AVM), one (2%) was
from a bleeding Dieulafoy’s lesion, one (2%) was a bleeding
polyp in the duodenum, and two (4%) were diverticular bleeds.
Forty-one (84%) were from upper gastrointestinal tract and
eight (18%) from lower gastrointestinal tract as defined previously. The detail of the GIB location and type is shown in Table
2. Most of the bleeding sites, 41 (84%), were within the reach of
DOAE for diagnosis and treatment during the same procedure.
Details of the subgroup analyses can be seen in Table 3. Enteroscopy was performed in 13 (46%) of the 28 episodes and was
able to detect 13 individual GIB sites. Treatment was performed
using either argon plasma coagulation or through injection of a
sclerosing agent. Patients with GIB who underwent enteroscopy
as the initial test and therapy during the first 24 hours of presentation to the hospital (group C) achieved significantly faster
resolution of GIB than patients who had delayed enteroscopy
after other imaging modalities had been performed (group B).
In comparing the number of transfusions, patients in group C
received significantly fewer units of blood when compared with
groups A and B, 1.3 vs. 4.1 and 6.3 (p = 0.001), respectively.
The number of diagnostic tests performed on patients in group
C averaged 1.1 per episode, which was significantly fewer than
2.4 and 3.5 for groups A and B (p = 0.005).
Discussion
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) reports have shown a steady
increase in the number of VAD implants as a bridge to transplant or as destination therapy during the last 5 years. This is,
in part, because of the VAD’s smaller size, ease of implant, and
decrease in complication rates.3

Stomach
Duodenum
Jejunum
Ileum
Colon

Number of
Lesions

Type of Lesion

7 (14%)
20 (41%)
13 (26%)
1 (2%)
8 (16%)

7 AVM
18 AVM, 1 Dieulafoy’s lesion, 1 polyp
13 AVM
1 AVM
6 AVM, 2 diverticulosis

*Some individuals had more than one bleeding lesion.
AVM, arteriovenous malformation.

Recent studies of GIB in VAD patients showed that 18%–
40% develop GIB while receiving VAD therapy and have also
shown a difference between the pulsatile VAD and CFVAD.8–10
Crow et al.10 found that patients with CFVAD had GIB rates 10
times as much as patients with pulsatile VADs. The shift from
the early VADs, which used a pulsatile system to mimic normal cardiac output, to the modern CFVAD being used today
has come with an increased propensity for patients to develop
GIB.10 With the increasing number of implanted CFVADs,
many have postulated the reasons for the increased propensity to develop GIB in this population. In as early as 1958,
Heyde11 found increased rates of GIB in patients with aortic
stenosis. Modern day CFVADs produce a continuous flow,
which is similar to what is seen in patients with severe aortic
stenosis. The severely stenotic valve creates high shear stress
across the aortic leaflets leading to denaturing of von Willebrand factor (vWF) multimers, which promotes their destruction.10,12 With the proteolytic cleavage of this factor, patients
develop acquired vWF disease that increases their propensity
to bleed.13In addition, CFVADs are known to alter the visceral circulation leading to an increased intraluminal pressure
which leads to dilation of mucosal veins and AVM development.14 CFVADs also decrease gastrointestinal mucosal perfusion, which may lead to mucosal ischemia and an increased
propensity to develop bleeding at those sites.15 The cause of
GIB is likely a combination of all of these factors. Interestingly,
after removal of the VAD with either cardiac recovery or a
transplant, the episodes of GIB abate.9
Each individual, when presenting with an episode of GIB, may
require readmission, reversal or cessation of anticoagulation,
multiple imaging modalities to attempt to identify and treat
the source of bleeding, and last, multiple transfusions. Each
discontinuation of anticoagulation places the patient at risk
for device thrombosis and potential embolization; thus a
speedy diagnosis and therapy are important.5 Episodes of
GIB may not be simply controlled with lowering INR or
stopping the antiplatelet agent. Our study found that 64%
of our patients had an INR <1.5 on presentation suggesting
that the INR alone was not responsible for the bleeding. Each
diagnostic test requires time to complete and most require a
bowel preparation that can affect the patient’s hemodynamics
caused by dehydration. During the work-up phase, patients
receive multiple transfusions that increase the risk of antibody
development and can affect the ability of the patient to receive
a future heart transplant.16 Most importantly, despite recent
improvements in technology, the traditional algorithms we use
to treat GIB were primarily designed for the general population
and are not specific for VAD patients.
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Table 3.  Subgroup Analysis of Gastrointestinal Bleeding

Episodes
Enteroscopy
Average transfused packed red cells
Days to treatment
Average number of tests performed

Group A: Traditional
Without Enteroscopy

Group B: Traditional
With Enteroscopy

Group C: New
Management Algorithm

p Value

15
Never
4.1
n/a
2.4

6
Late
6.3
5.3
3.5

7
Early
1.3
0.4
1.1

0.001
0.0002
0.005

Group A: episodes where no diagnosis was ever made and patients did not undergo an enteroscopy. Group B: episodes that underwent
multiple diagnostic/therapeutic modalities with enteroscopy being performed >24 hours after the admission for treatment. Group C: episodes
where enteroscopy was performed within 24 hours of presentation.

Technology has seen many improvements during the last
decade, especially when examining the small bowel. Our
results showed that the majority of lesions were seen in the
small intestine with the duodenum, jejunum, and ileum
accounting for 69% of all lesions encountered. Aggarwal et al.3
showed that 57% of the patients they identified had the upper
gastrointestinal tract including the proximal small bowel as the
source of bleeding with 44% of them experiencing recurrent
bleeding. In their cohort of patients, Elmunzer et al.17 discovered that almost all subjects sustained hemorrhage from an
upper gastrointestinal source which confirms our belief that
the initial focus for a source needs to be the proximal gastrointestinal tract.
Bleeding from the small intestine used to be difficult to diagnose because of the lack of adequate instruments to visualize
the lumen with surgery being the only option.14 In 2001, the
emergence of capsule endoscopy allowed us to visualize the
lumen of the small intestine.18 The capsule, once swallowed,
takes multiple images of the small bowel to identify the source
of bleeding as it traverses through the intestine.19 Because capsule endoscopy is purely diagnostic, once a lesion is identified,
patients require another procedure for treatment.20
In early 2001, a new technology called DOAE was created
and was being used to treat GIB. Yamamoto et al.21 reported on
the first use of a double-balloon enteroscope which allowed
access to the duodenum, jejunum, and ileum not only for visualization but also for concurrent treatment. The technology
uses an enteroscope backloaded with an overtube to visualize
the small intestine.19 The overtube and endoscope each have
a balloon on the end; once the scope enters the small bowel,
the balloons are sequentially inflated and deflated while the
overtube is retracted and the enteroscope is advanced.19 This
congruent sequence “pleats” the small bowel over the enteroscope allowing it to advance further in the small bowel. Since
2001, single-balloon enteroscopy and spirus enteroscopy have
also emerged. Single-balloon enteroscopy uses an overtube
like in double-balloon enteroscopy, whereas spirus enteroscopy uses a helical overtube which is also backloaded over the
enteroscope. The overtube has raised ridges wrapped circumferentially, similar to a cork-screw, and when rotated, will pleat
the bowel in a circular manner over the overtube allowing for
the visualization of the small bowel.22 Diagnostic yields, when
compared between single-balloon enteroscopy and spiral
enteroscopy, are not statistically significant,23 and the rate of
complications remains low. Complications of these technologies, when used exclusively for diagnosis, are less than 1%
but may approach 4% when used for treatment.24 Elmunzer et
al.17 point out that enteroscopy is safe and essential to evaluate

the gastrointestinal tract and paramount to treatment of GIB
in patients with a VAD.17 Each of these new technologies has
been developed during the last decade and offer VAD patients
with GIB a quick diagnosis and therapy of the most commonly
found lesions in the small bowel, thus eliminating additional
tests and reducing the time to treatment.
Looking at the characteristics of the patients in our study,
patients with a pulsatile VAD did not experience a single episode thus, all of our GIB was observed in CFVAD. The majority
of patients (92%) presented with a sentinel bleed within the
first year of implant. The most common location of GIB was
in the duodenum and jejunum (67%), whereas the colon only
accounted for 16%. With most of our lesions being confined to
the proximal small bowel (stomach, duodenum, and jejunum),
enteroscopy was successful in treating these lesions on the first
pass. Approximately one third of the GIB lesions were confined to the jejunum and ileum and would not be diagnosed
without capsule endoscopy or DOAE and be missed. Patients
who received enteroscopy on initial presentation, received
fewer units of packed red blood cells, fewer diagnostic tests,
and had a decreased time to diagnosis and treatment when
compared with patients who received DOAE after other tests
had been done which failed to localize bleeding or in patients
who did not have DOAE done at all. The episodes where the
new technology of DOAE was used did not experience any
complications or adverse events. This discovery led us to create
a new GIB work-up algorithm (Figure 2) designed specifically
for the VAD patient focusing on performing DOAE early in a
patient’s hospital course.
The focus of our new algorithm is prompt assessment of
the most common location of bleeding in the gastrointestinal
tract. Lower GIB can be screened at presentation by digital
rectal examination and a careful medical history to identify
conditions which can make the patient more prone to bleed
from the colon. If lower GIB is suspected, colonoscopy should
be scheduled. Otherwise, all patients without a history of lower
GIB should be scheduled for a DOAE based on the frequency
and most common locations of the offending lesions. Our
data suggest a potential advantage of incorporating our new
algorithm for the management of GIB in VAD patients.
Although our results proved to have statistical significance,
our study has limitations. Our study was performed at a single
center where the number of the patients is relatively small and
a multicenter study would be ideal. A standardization of the
management of GIB is essential; however, it is difficult because
most centers are using an individually constructed management plan. In addition, the definition of GIB needs to be
standardized; studies presented in the literature use multiple
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definitions and make comparison of significant events very difficult between centers. Randomized comparison between the
traditional GIB algorithm and our new algorithm will be difficult at our institution because we are no longer following the
traditional algorithm.
Conclusion
With the population of VAD patients growing each year,
physicians will be increasingly forced to deal with complications of this therapy. We identified that most GIB lesions in
patients with CFVAD are AVMs and are located either in the
stomach, duodenum, jejunum, or ileum. Noting the location
of these lesions, only DOAE allows for the visualization and
treatment of these lesions to occur during the same procedure
without having to take the patient to surgery. The prompt initiation of enteroscopy, either double-balloon, single-balloon, or
spirus, can allow for rapid identification and treatment of these
lesions, thereby limiting the number of tests performed and
decreasing the number of transfusions that the patients receive.
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